Research progress of abnormally expressed lncRNAs in glioma

doi:10.12092/j.issn.1009-2501.2018.05.017

Abstract

Abstract:

With the development of whole genome and transcriptome sequencing technologies, a growing body of long noncoding RNAs (lncRNAs) has been identified. It showed that lncRNAs were important for the diagnosis, treatment and prognosis of glioma. At present, more than 20 abnormal expression lncRNAs have been identified that may play a role in glioma pathogenesis. In this paper, we reviewed those lncRNAs in glioma in hope of helping to identify potential biomarkers and improve the diagnosis and the treatment of glioma.

Key words: glioma, lncRNAs, pharmacological effects, biomarkers

CLC Number:

R739

GAO Yuanfeng, LI Shan, LIU Lin, OUYANG Rong. Research progress of abnormally expressed lncRNAs in glioma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 586-591.

References

［1］茆晨雪，周宏灏，刘昭前.弥漫性胶质瘤生物标志物的发现及研究进展［J］.中国临床药理学与治疗学，2016, 21(1): 93-98.
［2］Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma［J］. J Neurooncol, 2012,108(1): 11-27.
［3］Hajjari M, Salavaty A. HOTAIR: an oncogenic long noncoding RNA in different cancers［J］. Cancer Biol Med,2015,12(1): 1-9.
［4］Pastori C, Kapranov P, Penas C, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation［J］. Proc Natl Acad Sci USA, 2015,112(27): 8326-8331.
［5］Ke J, Yao YL, Zheng J, et al. Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326［J］. Oncotarget,2015,6(26): 21934-21949.
［6］Shi J, Dong B, Cao J, et al. Long non-coding RNA in glioma: signaling pathways［J］. Oncotarget,2017,8(16):27582-27592.
［7］Ariel I, Sughayer M, Fellig Y, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma［J］. Mol Pathol,2000,53(6):320-323.
［8］Berteaux N, Lottin S, Monte D, et al. H19 mRNAlike noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1［J］. J Biol Chem,2005,280(33): 29625-29636.
［9］Zhang T, Wang YR, Zeng F, et al. LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675［J］. Eur Rev Med Pharmacol Sci,2016,20(23):4891-4897.
［10］Li C, Lei B, Huang S, et al. H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma［J］. Am J Transl Res,2015,7(10):1747-1764.
［11］Jiang P, Wang P, Sun X, Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy［J］. Onco Targets Ther,2016,9:3501-3509.
［12］Zhang X, Sun S, Pu JK, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma［J］. Neurobiol Dis,2012,48(1):1-8.
［13］Li DX, Fei XR, Dong YF, et al. The long non-coding RNA CRNDE acts as a ceRNA and promotes glioma malignancy by preventing miR-136-5p-mediated downregulation of Bcl-2 and Wnt2［J］. Oncotarget,2017,8(50):88163-88178.
［14］Li H, Li Q, Guo T, et al. LncRNA CRNDE triggers inflammation through the TLR3-NF-κB-Cytokine signaling pathway［J］. Tumour Biol,2017,39(6):1010428317703821
［15］Wang Y, Wang Y, Li J, et al. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling［J］. Cancer Lett, 2015,367(2):122-128.
［16］Han Y, Zhou L, Wu T, et al. Downregulation of lncRNA-MALAT1 affects proliferation and the expression of stemness markers in glioma stem cell line SHG139S［J］. Cell Mol Neurobiol, 2016,36(7):1097-1107.
［17］Ma J, Wang P, Yao Y, et al. Knockdown of long non-coding RNA MALAT1 increases the blood-tumor barrier permeability by up-regulating miR-140［J］. Biochim Biophys Acta,2016,1859(2):324-338.
［18］He C, Jiang B, Ma J, et al. Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients［J］. APMIS,2016,124(3):169-174.
［19］Zhen L, YunHui L, Hong-Yu D, et al.Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis［J］. Tumour Biol,2016,37(1):673-683.
［20］Wang Q, Zhang J, Liu Y, et al. A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma［J］. Cancer Lett, 2016,373(2):251-259.
［21］Guo H, Wu L, Yang Q, et al.Functional linc-POU3F3 is overexpressed and contributes to tumorigenesis in glioma［J］. Gene,2015,554(1):114-119.
［22］Zhu Y, Zhang X, Qi L, et al. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas［J］. Oncotarget,2016,7(12):14429-14440.
［23］Liu H, Lv Z, Guo E. Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition［J］. Int J Clin Exp Pathol, 2015,8(8):9140-9146.
［24］Ma CC, Xiong Z, Zhu GN, et al. Long non-coding RNA ATB promotes glioma malignancy by negatively regulating miR-200a［J］. J Exp Clin Cancer Res, 2016,35(1):90.
［25］Hu L, Lv QL, Chen SH, et al. Up-regulation of long non-coding RNA AB073614 predicts a poor prognosis in patients with glioma［J］. Int J Environ Res Public Health,2016,13(4):433.
［26］Su R, Cao S, Ma J, et al. Knockdown of SOX2OT inhibits the malignant biological behaviors of glioblastoma stem cells via up-regulating the expression of miR-194-5p and miR122［J］. Mol Cancer, 2017,16(1):171.
［27］Cui B, Li B, Liu Q, Cui Y, et al.LncRNA CCAT1 promotes glioma tumorigenesis by sponging miR-181b［J］.J Cell Biochem,2017,118(12):4548-4557.
［28］Wu F, Zhang C, Cai J, et al. Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma［J］. Oncotarget,2017,8(32):53110-53123.
［29］Wang P, Ren Z, Sun P. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation［J］. J Cell Biochem,2012,113(6):1868-1874.
［30］Gong X, Huang M. Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/β-catenin signal pathway［J］. Cancer Gene Ther,2017,24(9):381-385.
［31］Li J, Bian EB, He XJ, et al. Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas［J］. Int J Oncol, 2016,48(2):723-733.
［32］Yao Y, Ma J, Xue Y, et al. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152［J］. Cancer Lett,2015,359(1):75-86.
［33］Qin X, Yao J, Geng P, et al.LncRNA TSLC1-AS1 is a novel tumor suppressor in glioma［J］. Int J Clin Exp Pathol,2014,7(6):3065-3072.
［34］Yao J, Zhou B, Zhang J, et al. A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells［J］. Tumour Biol, 2014,35(8):7935-7944.
［35］Yue H, Zhu J, Xie S, et al.an antisense long noncoding RNA, regulates cell proliferation of glioma［J］. Biomed Pharmacother,2016,81:203-209.
［36］Li J, Zhang M, An G, et al. lncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis［J］. Exp Biol Med,2016,241(6):644-649.
［37］Cai H, Xue Y, Wang P, et al. The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144［J］.Oncotarget, 2015,6(23):19759-19779.
［38］Feng S, Yao J, Chen Y, et al. Expression and functional role of reprogramming-related long noncoding RNA (lincRNA-ROR) in glioma［J］. J Mol Neurosci,2015,56(3):623-630.
［39］Zhao X, Wang P, Liu J, et al. Gas5 Exerts Tumor-suppressive functions in human glioma cells by targeting miR-222［J］.Mol Ther, 2015,23(12):1899-1911.
［40］Wang P, Liu YH, Yao YL et al. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21［J］. Cell Signal, 2015,27(2):275-282.
［41］Gao YF, Wang ZB, Zhu T, et al. A critical overview of long non-coding RNA in glioma etiology 2016: an update［J］. Tumour Biol, 2016, 37(11):14403-14413.
［42］Wang X, Song X, Glass CK, et al.The long arm of long noncoding RNAs: roles as sensors regulating gene transcriptional programs［J］. Cold Spring Harb Perspect Biol, 2011,3(1):a003756.
［43］van Bakel H, Hughes TR. Establishing legitimacy and function in the new transcriptome［J］. Brief Funct Genomic Proteomic, 2009, 8: 424-436.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[3]	DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
[4]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[5]	LU Chenyu, YANG Jun, LIU Yixi, ZHENG Yun. Function and regulation of miRNAs associated with Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 775-783.
[6]	CHE Jinjing. Application of biomarkers in clinical development of biologics and bioanalytical strategies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 22-31.
[7]	FENG Han, ZHOU Hong-Hao, 欧Yang-Dong-Sheng . Chemical constituents and Pharmacology of Eucommia ulmoides Oliv. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(6): 713-720.
[8]	YAN Yuan-liang, QIAN Long, GONG Zhi-cheng. Meta-analysis of temozolomide combined with IMRT in treatment of postoperative malignant glioma in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 64-69.
[9]	LI Shu, HONG Yun, ZHANG Gen-bao, YANG Shi-yong, ZHOU Yan-fang, TAO Bang-bao. Expression and significance of TKTL1 in glioma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 638-642.
[10]	WANG Jian-kun, ZHU Xuan-xuan, SUN Jian-guo. Progress of pharmacological effects and pharmacokinetics of stilbene glycoside from Polygonum multiflorum Thunb [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(12): 1426-1430.
[11]	LAI Yan-ping, LIU Yan-qiang. Significance of GABA_A receptors in the development of some neuropsychiatric diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(2): 208-212.
[12]	ZOU Jing, YAO Hong-Hong, HU Gang. Agonists of group II and III metabotropic glutamate receptors reverse LPS-induced glutamate uptake inhibition in C6 glioma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 626-629.
[13]	REN Hong-can, WANG Cuang-ji, A Ji-ye, HAO Hai-ping, SUN Jian-guo, ZHA Wei-bin, YAN Bei. Advances of analysis technology and data processing in metabonomics study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1332-1338.
[14]	WANG Fang, YAO Hong-hong, HU Gang. Group I and III metabotropic glutamate receptors agonists reverse 1-methyl-4-phenylpyridinium-induced glutamate uptake inhibition in C6 glioma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(10): 1096-1099.
[15]	XU Bi-Lian, WU Tie, WANG Hui. Current advances on the pharmacological effects of total flavones of epimedium [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 105-107.